Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Budesonide Patch Testing

Budesonide Patch Testing Abstract When I editorialized on patch testing for corticosteroid allergy, budesonide was unavailable in the United States.1 Late in 1994, the US Food and Drug Administration approved a new nasal inhaler known as Rhinocort, which is budesonide made available in a metered-dose apparatus. The 7-g canister contains 200 metered doses, each containing approximately 32 mg of micronized budesonide. I had the opportunity to conduct a patch test on a patient with 0.1% budesonide in petrolatum, and an extreme reaction (3+) developed at 96 hours. I recently retested him with budesonide sprayed directly into a Finn chamber and applied to his back. This was done with one activation directly to the Finn chamber, with successive Finn chambers containing additional activations, up to a total of nine activations. He underwent retesting with 0.1% budesonide in petrolatum. At 48 hours, all of the tests showed equally positive results, indicating that one activation References 1. Rietschel RL. Patch testing for corticosteroid allergy in the United States . Arch Dermatol. 1995;131:91-95.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Budesonide Patch Testing

Rietschel, Robert L.
Archives of Dermatology , Volume 131 (12) – Dec 1, 1995
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/budesonide-patch-testing-XHs49yOW43

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1995.01690240132032
Publisher site
See Article on Publisher Site

Abstract

Abstract When I editorialized on patch testing for corticosteroid allergy, budesonide was unavailable in the United States.1 Late in 1994, the US Food and Drug Administration approved a new nasal inhaler known as Rhinocort, which is budesonide made available in a metered-dose apparatus. The 7-g canister contains 200 metered doses, each containing approximately 32 mg of micronized budesonide. I had the opportunity to conduct a patch test on a patient with 0.1% budesonide in petrolatum, and an extreme reaction (3+) developed at 96 hours. I recently retested him with budesonide sprayed directly into a Finn chamber and applied to his back. This was done with one activation directly to the Finn chamber, with successive Finn chambers containing additional activations, up to a total of nine activations. He underwent retesting with 0.1% budesonide in petrolatum. At 48 hours, all of the tests showed equally positive results, indicating that one activation References 1. Rietschel RL. Patch testing for corticosteroid allergy in the United States . Arch Dermatol. 1995;131:91-95.Crossref

Journal

Archives of Dermatology – American Medical Association

Published: Dec 1, 1995

There are no references for this article.